Registration of the first human vaccine against the highly pathogenic avian influenza A(H5N1) virus: Considerations;Het eerste in Europa geregistreerde humane vaccin tegen de hoogpathogene vorm van een vogelgriepvirus: Overwegingen

Nederlands Tijdschrift voor Geneeskunde

Volumn 152, Issue 39, 2008, Pages 2113-2115

  De Jong, J C ^a   Osterhaus, A D M E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AVIAN INFLUENZA VACCINE;

AVIAN INFLUENZA; HUMAN; IMMUNITY; MEDICAL PRACTICE; MEDICAL SOCIETY; NETHERLANDS; PANDEMIC; SHORT SURVEY;

ADJUVANTS, IMMUNOLOGIC; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 53249129545     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (11)

1. Jong JC de, Claas ECJ, Osterhaus ADME, Webster RG, Lim WL. A pandemic warning? Nature. 1997;389:554.
2. El Sahly HM, Keitel WA. Pandemic H5N1 influenza vaccine development: an update. Expert Rev Vaccines. 2008;7:241-7.
3. Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet. 2006;368:991-7.
4. Wu WL, Chen Y, Wang P, Song W, Lau SY, Rayner JM, et al. Antigenic profile of avian H5N1 viruses in Asia from 2002 to 2007. J Virol. 2008;82:1798-807.
5. Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007;370:580-9.
6. Leroux-Roels I, Bernhard R, Gérard P, Dramé M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE. 2008;3:e1665.
7. Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, Pistoor FH, et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE. 2008;3:e1401.
8. Itoh Y, Ozaki H, Tsuchiya H, Okamoto K, Torii R, Sakoda Y, et al. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques. Vaccine. 2008;26:562-72.
9. Kreijtz JHCM, Süzer Y, Mutsert G de, Brand JMA van den, Amerongen G van, Schnierle BS, et al. Recombinant modified vaccinia virus Ankara expressing HA confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis. [ter perse].
10. Kendirgi F, Yun NE, Linde NS, Zacks MA, Smith JN, Smith JK, et al. Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1. Hum Vaccin. [ter perse].
11. Kreijtz JH, Mutsert G de, Baalen CA van, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol. 2008;82:5161-6.